Biden-Harris Administration moves to expand coverage for anti-obesity medications

By Stacy M. Brown, NNPA Newswire Senior National CorrespondentAs the incoming administration prepares to enact sweeping changes to health policy, including Robert F. Kennedy Jr.’s controversial appointment to lead the Department of Health and Human Services (HHS), the Biden-Harris Administration is addressing a critical health issue: obesity. A new proposal aims to expand Medicare and Medicaid coverage for anti-obesity medications (AOMs), potentially providing millions of Americans access to life-saving treatments.Obesity, which affects an estimated 42 percent of the U.S. population, is a chronic disease linked to increased mortality and serious conditions such as diabetes, cardiovascular disease, and stroke. Despite recent advancements in obesity treatment, including medications that can reduce heart attack risk and Type 2 diabetes, these drugs remain prohibitively expensive, often costing up to $1,000 per month without insurance.The Biden-Harris proposal seeks to broaden Medicare and Medicaid coverage for these medications, reducing out-of-pocket costs by up to 95 percent for some enrollees. The expanded coverage could benefit an estimated 3.4 million Medicare beneficiaries and 4 million Medicaid enrollees. “This proposal ensures that Americans can access treatments they need to lead healthier lives without financial burden,” a senior administration official stated.Kennedy’s Controversial Appointment Raises Questions About the Future of HealthcareThe...